In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00.
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $84.00. Discover outperforming stocks and invest smarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback